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INTRODUCTION
Malignant ovarian tumors is an important issue of re-
productive health in both Indonesia and another coun-
try, because of the high incidence and at early stage
is often asymptomatic, so that at the time of diagnosis
more than two-thirds of cases of malignant ovarian
tumors had reached an advanced stage, with high mor-
tality and often referred to as the silent killer.1
The proportion of malignant ovarian tumors in Dr.
Hasan Sadikin Hospital in 2008 was 19.77% from
1228 gynecologic cancer,2 whereas in Dr. Cipto Ma-
ngunkusumo in the year 1978 - 1982 was 10.5% from
3874 gynecologic cancer.3 Based on the Global Can-
cer Statistics 2002, incidence of malignant ovarian tu-
mors in developing countries is higher than developed
countries, ie more than 9/100,000 women, except for
Japan (6.4/100,000).4
Ovarian cancer comprises a heterogeneous group
of tumors of three major types: epithelial, germ cell
and sex cord stromal. Epithelial tumors arise from the
coelomic mesothelium represent about 82% of all
ovarian malignancies. The predominant cell types are:
serous, mucinous, endometrioid, clear cell, and Bren-
ner tumor. The malignant germ cell tumors are be-
lieved to arise from primitive germ cells in the ovary.
These tumors represent about 5% of all ovarian ma-
lignancies. They include dysgerminoma, embryonal
cancer, endodermal sinus tumor, choriocarcinoma and
malignant teratomas. The sex cord stromal neoplasms
are derived from mesenchymal stem cells in the ovar-
ian cortex and represent about 10% of all ovarian tu-
mors. They include granulosa-theca cell tumors,
granulosa cell tumors (GCTs) and Sertoli-Leydig cell
tumors.5
Abstract
Objective: This research was carried out to discover the corre-
lation between the AMH serum in patients with malignant ovarian
tumor of epithelial type with the Ki-67 expression as a marker of
proliferation, therefore it was expected through the research to know
the role of AMH in the inhibition of proliferation and growth of ma-
lignant ovarian tumor of epithelial type.
Method: The study design was cross-sectional, with data ob-
tained retrospectively from 24 medical records of patients with ma-
lignant ovarian of epithelial type, who had been examined for AMH
levels in 2009, along with the sample in the form of preparation of
paraffin embedded tissue of malignant ovarian tumor patients, who
fulfilled the inclusion criteria. Furthermore examination of Ki-67
expression was performed with the statistical analysis using the rank
Spearman analysis.
Result: There was a negative correlation between AMH levels
and Ki-67 expression in patients with malignant ovarian tumors of
epithelial (r = -0.652, p < 0.05).
Conclusion: These data indicate a significant negative correla-
tion between serum AMH levels and Ki-67 expression in epithelial
ovarian cancer patients.
[Indones J Obstet Gynecol 2011; 35-2: 87-90]
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Abstrak
Tujuan: Penelitian ini untuk mencari korelasi antara kadar se-
rum AMH penderita karsinoma ovarium dengan ekspresi Ki-67 se-
bagai petanda proliferasi, sehingga diharapkan dapat diketahui pe-
ran AMH dalam penghambatan proliferasi dan pertumbuhan kar-
sinoma ovarium.
Metode: Rancangan penelitian adalah potong silang, dengan
data diperoleh secara retrospektif dari rekam medik 24 penderita
karsinoma ovarium, yang sudah diperiksa kadar AMHnya pada ta-
hun 2009, beserta sampel yang berupa sediaan blok parafin pen-
derita tumor ganas ovarium tersebut yang memenuhi kriteria inklu-
si. Selanjutnya dilakukan pemeriksaan ekspresi Ki-67 untuk dicari
korelasinya dengan kadar AMH, menggunakan analisis statistik
rank Spearman.
Hasil: Terdapat korelasi negatif antara kadar AMH dan histo-
skor Ki-67 pada penderita karsinoma ovarium (r = -0,652; p < 0,05).
Kesimpulan: Data ini menunjukkan korelasi negatif yang signi-
fikan antara kadar serum AMH dan ekspresi Ki-67 pada karsinoma
ovarium. Bersamaan dengan literatur terkini, hasil penelitian ini
memberikan tambahan data mengenai peranan AMH dalam meng-
urangi proliferasi sel tumor.
[Maj Obstet Ginekol Indones 2011; 35-2: 87-90]
Kata kunci: anti-müllerian hormone, Ki-67, Müllerian inhibi-
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Therapy of ovarian malignant tumors, beginning
with surgery to remove the tumor burden, up to leave
a tumor with a size < 1.5 cm that will be followed
by chemotherapy. Giving chemotherapy has severe si-
de effects and still have a fairly high failure due to
resistance, therefore another method is required in ad-
dition to increasing remission and disease-free period,
so that will improve the quality of life.1 Anti-mülle-
rian hormone/müllerian inhibiting substance (AMH/
MIS) that can inhibit growth of Müllerian duct is ex-
pected to inhibit the growth of ovarian cancer because
of ovarian cancers are also derived from Müllerian
duct precursors.
AMH is a member of the transforming growth fac-
tor (TGF) superfamily. Anti-Müllerian hormone, has
a role in the treatment of epithelial ovarian cancer.5-6
This glycoprotein has a broad function in epithelial-
mesenchymal interactions, cell growth, extracellular
matrix production, and tissue remodeling.6 In physi-
ological conditions AMH inhibited the progression of
Müllerian duct male fetuses, whereas in women AMH
plays a role in foliculogenesis.6 Epithelial ovarian
cancer is originated from coelomic epithelium which
is of Müllerian origin and thus, expresses MIS/AM-
HRII. Based on the physiological inhibiting role of
AMH on the müllerian ducts, researchers have de-
monstrated that AMH inhibits epithelial ovarian can-
cer cell both in vitro and in vivo.7-11 In vitro AMH
inhibits the growth of ovarian epithelial cell line
(HOSE 6 - 3) and human ovarian cancer cell lines
(OVCAR-8) by proliferation of p16 protein, a part of
inhibitor of cyclin-dependent kinase (INK4) family.12
Inhibitors of cyclin-dependent kinase is a family of
cyclin-dependent kinase inhibitors (CDKI), which
will inhibit cyclin and cyclin-dependent kinase com-
plexes (CDK). Cyclins and CDK complexes have im-
portant regulatory roles during cell cycle progression.
Based on these findings, there is the possibility that
AMH could be used to increase the success of che-
motherapy in ovarian cancer.5,12
The unpublished study in 2009, on 40 patients with
malignant ovarian tumors, found some elevated levels
of AMH in 32 patients with ovarian cancer, 6 patients
with malignant germ cell tumors, and 2 patients with
GCT. Increased levels of AMH may be associated
with tumor progression, which among others relate to
the level of proliferation. CA125 is commonly used
for monitoring ovarian cancer, no increase in 10 -
20% of women with ovarian cancer and does not in-
crease with tumor size. In addition, CA125 can be
elevated in benign conditions, such as endometriosis.
Therefore, the level of proliferation is better charac-
terized by the proliferation markers, such as Ki-67
expression. Ki-67 protein (antigen) is stable, has a
half-life of about 60 - 90 minutes and can be found
at all stages of the cell cycle except the G0 phase, so
that Ki-67 is a good marker of proliferation,13 wher-
eas other markers such as proliferating cell prolifera-
tion nuclear antigen (PCNA) and JC1 increase also in
cells that are not proliferate.14
From the prior illustration, AMH including TGF-β
family that play a role as a tumor suppressor, pre-
venting proliferation of Müllerian duct during em-
bryogenesis and possibly also growth an ovarian can-
cer that embriological precursor the same as Mülle-
rian duct, so that alleged that the expression of AMH
reduces ovarian cancer cell proliferation that can be
characterized by expression of Ki-67.
Based on these reasons, the author wanted to know
if there is a correlation between serum AMH levels
of ovarian cancer patients who was investigated in
2009 but not yet published, with Ki-67 expression as
a marker of proliferation, which is expected to note
the role of AMH in the inhibition of proliferation and
growth of ovarian cancer.
SUBJECT
The subject is paraffin embeded tissue of ovarian can-
cer patients who was proven by pathological anatomy
and have undergone the examination of serum AMH
levels in 2009.
METHOD
The design of this study was a cross-sectional study.
The data was obtained retrospectively from medical
records of ovarian cancer patients who have examined
levels of AMH and paraffin blocks of available stocks
in the Anatomical Pathology Department at Dr. Hasan
Sadikin Hospital.
RESULTS
Of the 32 patients with ovarian cancer who AMH
have examined, a total of 6 patients refused/unable to
be contacted to participate in the study and the two
stocks paraffin blocks could not be evaluated. The
number of samples can be examined in this study had
to meet minimum sample size, i.e. 23 subjects.
Table 1 shows that the average age of ovarian can-
cer patients was 44.8 years with a standard deviation
of 17.2 years and most are kind serosum (37.5%).
In this study, which compared the characteristics
of the study subjects consisted of age and type of
histology. According to Berek’s literature, the inci-
dence of ovarian carcinoma of age increased from 20
years to 80 years, then subsequently decreased, wher-
eas the peak incidence is age 50 - 60 years.1 In the
research, the results are shown Table 1, the average
age of patients with ovarian carcinoma was 44.8
years. This is consistent with the theory that ovarian
carcinomas are rare in the young ages.
Table 1. Characteristics of subjects by age and histology
results in patients with ovarian cancer (n = 24)
Characteristic Total
Age (years old)
• Median: 49 –
• Range: 22 - 72 –
Hystologic type
• Serous adenocarcinoma 9
• Mucinous adenocarcinoma 8
• Endometrioid adenocarcinoma 6
• Clear cell carcinoma 1
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Table 2. The results of Ki-67 expression in ovarian cancer
patients
Ki-67 Total %
Intensity
• Weak  4 16.6
• Moderate 10 41.7
• Strong 10 41.7
Distribution
• < 20%  2  8.3
• 20% - 50%  5 20.8
• 50% - 80% 10 41.7
• > 80%  7 29.2
Serous ovarian tumor incidence is 40% of all epi-
thelial ovarian tumors, 50% are malignant, 33% are
benign, and 17% are borderline. The incidence of mu-
cinous ovarian tumor is 8 - 10% of all epithelial tu-
mors, as much as 80% are benign, 15% are borderline,
and 5% are malignant. The incidence of endometrioid
ovarian tumors is 6 - 8% of epithelial malignancies,
as much as 80% are malignant and 20% are usually
borderline. The incidence of carcinoma of clear cell
type as much as 6% of all epithelial malignancies and
entirely malignant.1 In this study the most is the kind
serous type (37.5%) and the rarest is the kind of clear
cell (4.17%) and this is in accordance with incidence
of each type of malignancy.
Table 2 demonstrates the intensity of Ki-67 in pa-
tients with ovarian cancer most powerful classified
and moderate (41.7%), weakness (16.6%). While most
are based on the distribution of between 50% - 80%
(41.7%) remaining > 80% (29.2%); 20% - 50%
(20.8%) and < 20% (8.3%).
In the study Kupryjanczyk and Isola, Ki-67 as a
variable known to increase proliferation in tissues
with high mitotic index and may affect the initial
spread of malignant tumors ovarium.15,16
 In this study, as shown in Table 2 obtained inten-
sity of Ki-67 in patients with ovarian carcinoma is a
relatively strong majority and moderate (41.7%),
whereas the distribution of Ki-67 in patients with ova-
rian carcinoma the highest is 50% - 80% (41.7%).
Furthermore, based on the value of the intensity
and distribution of Ki-67 by making the scoring for
the intensity that is:17
negative = 0; weak = 1; medium = 2, and strong = 3
and scoring for distribution are:
< 20% = 1; 20% - 50% = 2; 50% - 80% = 3; and >
80% = 4
can be calculated the amount of Ki-67 expression re-
vealed by histoscore:
histoscore = (intensity + 1) x distribution
Next histoscore level be categorized according to the
calculation:
Weak: if the score value 1 - 4
Moderate: if the score value 6 - 9
Strong: if the score value of 12 - 16
Histoscore calculation results are presented in the
following table.
Table 3. AMH comparison based on histoscore
Ki-67
AMH
X SD
Weak 9.604 ± 6.528
Moderate 1.842 ± 0.195
Strong 1.229 ± 0.409
Table 3 shows the AMH comparison based on his-
toscore. The more higher AMH level the more lower
Ki-67 expression.
Note: AMH: Ki-67; y = 12.277 - 0.736*x; r = -0.652; p = 0.001
Figure 1 shows that, there is strong correlation bet-
ween AMH levels and the expression level of Ki-67
with r = -0.652. The higher levels of AMH, the lower
the level of proliferation that is characterized by Ki-67.
DISCUSSION
In this study, which compared the characteristics of
the study subjects consisted of age and type of his-
tology. According to the literature Berek, incidence
of age on ovarian cancer increased from 20 years to
80 years, then subsequently decreased, whereas the
peak incidence is age 50 - 60.1 The research results
are shown in Table 1, the average age of patients with
ovarian cancer was 44.8 years old. This is consistent
with the theory that ovarian cancers rarely occur du-
ring adolescence/young.
Serous ovarian tumor incidence is 40% of all epi-
thelial ovarian tumors, 50% are malignant, 33% are
benign, and 17% are borderline. The incidence of ova-
rian tumors mucinous is 8 - 10% of all epithelial tu-
mors, 80% are benign, 15% are borderline, and 5%
are malignant. The incidence of ovarian endometrioid
tumors is 6 - 8% of epithelial malignancies, 80% are
malignant and 20% usually are borderline. The inci-
dence of clear cell cancer type as much as 6% of all
epithelial malignancies and entirely malignant.1 In
this study the most frequent type is serosum (37.5%)
and least common is clear cell type (4.17%) and this
agrees with incidence of each type of malignancy.
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Figure 1. Correlation between elevated levels of AMH and the
level of expression of Ki-67
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In research Kupryjanczyk and Isola, Ki-67 as a
variable known to increase proliferation in a network
with a high mitotic index and can affect the initial
spread of malignant tumors ovarium.15-16
In this study, as shown in Table 2 obtained inten-
sity of Ki-67 in patients with ovarian cancer is a rela-
tively strong majority and moderate (41.7%), whereas
the distribution of Ki-67 in patients with ovarian can-
cer is the most 50% - 80% (41.7%).15,16
Table 3 shows the AMH comparison based on his-
toscore. The more higher AMH level is the more
lower Ki-67 expression. The mean AMH level is
9.604; 1.842; 1.229 which in correlation with a weak,
moderate, and strong Ki-67 successful expression.
Anti-müllerian hormone purified in vitro and in vi-
vo inhibits several malignant tumor cell lines derived
from human ovarian Müllerian duct,7,8,10,11 through
activation of p16 protein. Protein p16 is a CDKI that
slow the cell cycle and decrease the proliferation in
a way that phosphorylate proteins CDK inactivation
Rb.12 Anti-müllerian hormone inhibits growth of ova-
rian epithelial cell line (HOSE 6-3) and malignant tu-
mor cell lines of human ovarian (OVCAR-8) in vivo
studies conducted by research conducted Ha et al.11
Chin et al, rhMIS resulted in inhibition of cell line
NIH: OVCAR-3 (ovarian adenocancer).10
The level of cell proliferation can be marked for
example by expression of Ki-67.13 Ki-67 has a spe-
cific nature that is only found in the cells proliferate
and are not affected by DNA damage, making the
Ki-67 as a good marker of proliferation.13,16,18 Re-
search conducted Kohlberger et al, showed prolifera-
tive activity with Ki-67 marker, i.e. by 16.7% in be-
nign lesions, 76.5% in cancer ovarium.19
Based on the explanation above, the expected le-
vels of AMH is expressed in ovarian cancer patients
that the authors examined, can affect the proliferation
of these tumors. Figure 1 shows that the statistical
test by Spearman rank analysis on the degree of con-
fidence of 80% shows that there is a strong correlation
between AMH levels and the expression of Ki-67 are
categorized according to the results histoscore in
ovarian cancer patients with r = -0.652, p = 0.001 (p
value < 0.05), so the higher the levels of AMH, the
lower the level of proliferation that is characterized
by Ki-67.
SUGGESTION
These results prove that there is a negative correlation
between serum AMH levels with Ki-67 expression in
ovarian cancer, so it can support the results of other
studies using AMH as an ovarian cancer therapy in
vivo and in vitro, and is expected to later be used
directly in humans. Futhermore it needs to develop
genetically modified to synthesize AMH for therapeu-
tic purposes.
CONCLUSION
There is a strong correlation between elevated levels
of AMH and AMH decrease in proliferation.
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